Foxo Technologies Inc
delwinds.comWhat Do They Do?
Provides hospital and behavioral-health care to patients, and supplies biological materials to biotechnology, clinical research and pharmaceutical research customers.
10-K for FY2025, filed Apr 15, 2026Our Healthcare segment began with the acquisition of Myrtle on June 14, 2024, and includes RCHI, which was acquired on September 10, 2024.…View ↗
Our Life Science Services segment services the biotechnology, clinical research and pharmaceutical research industries focusing on the…View ↗
Vector is focused on sourcing and distributing high-quality biological materials, such as blood and urine, and providing data services to…View ↗
How Do They Make Money?
Patients and third-party payers pay for hospital and behavioral-health care as services are provided, at service, daily, per-discharge or diagnosis rates. Vector sells biological materials on agreed payment terms, while Labs collects royalties on Infinium Mouse Methylation Array sales.
10-K for FY2025, filed Apr 15, 2026Myrtle’s revenues relate to contracts with patients in which its performance obligations are to provide behavioral health care services to…View ↗
RCHI’s revenues relate to contracts with patients of BSF in which its performance obligations are to provide health care services to the…View ↗
Our Life Science Services segment’s revenue consists of revenue from Vector, which was acquired on September 19, 2025. The Company…View ↗
The Company has recorded minor amounts of revenues from its Labs segment during the years ended December 31, 2025 and 2024. Labs currently…View ↗
-
10-K for FY2025, filed Apr 15, 2026
FY2025 revenue by reportable segment ↗
$16.4M
-
10-K for FY2025, filed Apr 15, 2026
$16.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
HealthCares
Usage-based
10-K for FY2025, filed Apr 15, 2026 |
98% |
HealthCares, FY2025
$16.1M Sources
|
Usage-based |
|
Life Science Services
Sold outright
|
1.5% |
Life Science Services, FY2025
$252.5K Sources
|
Sold outright |
|
Labs
Licensed
|
0.1% |
Labs, FY2025
$13.9K Sources
|
Licensed |
|
Corporate Segment and Other Operating Segment
|
0.1% |
Corporate Segment and Other Operating Segment, FY2025
$15.1K Sources
|
Who Are Their Customers?
Patients receive hospital and behavioral-health services; payment arrangements commonly involve third-party payers such as Medicare, Medicaid and commercial insurers.
10-K for FY2025, filed Apr 15, 2026
Do Revenues Turn Into Profits?
No. It lost $12.4M in FY2025.
10-K for FY2025, filed Apr 15, 2026
−$10.3MView ↗
10-K for FY2025, filed Apr 15, 2026
−$12.4MView ↗
10-K for FY2025, filed Apr 15, 2026
−$4MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
$8.1MView ↗
- ▲ Now profitable
- vs −$522K in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 14, 2026
Open tableView ↗
-
Jul 29, 2026
Vector agreed to acquire four blood collection centers
Vector expects the centers to supply bio-products to its customers; closing is subject to required regulatory approvals.
Sources
8-K, filed Jul 29, 2026
On July 29, 2026, the Company issued a press release announcing that its subsidiary, Vector BioSource, Inc., has entered into a definitive…View ↗
-
May 28, 2026
FOXO licensed its epigenetics portfolio for commercialization
FOXO licensed its portfolio exclusively worldwide for commercialization in return for royalties; LongevityFP also received an option to acquire majority ownership of FOXO Labs.
Sources
8-K, filed May 28, 2026
(i) License. The Company and FLI granted LongevityFP Technologies an exclusive, worldwide license to commercialize the Company’s…View ↗
Growing. Revenue grew 136.4x in 4 years, from $120K in FY2021 to $16.4M in FY2025, about 242% a year.
From insurance to health services
The older report centered on saliva-based underwriting and consumer longevity reports, plus life insurance sales through third-party carriers; the latest centers on hospital and behavioral-health care and biological-material sourcing, while retaining an epigenetics division.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Apr 15, 2026Our Healthcare segment began with the acquisition of Myrtle on June 14, 2024, and includes RCHI, which was acquired on September 10, 2024.…View ↗
Our Life Science Services segment services the biotechnology, clinical research and pharmaceutical research industries focusing on the…View ↗
Our Labs segment is commercializing proprietary epigenetic biomarker technology to be used for underwriting risk classification in the…View ↗
Loading...
